Current Oncology Reports

, 21:14 | Cite as

TRK Inhibitors: Clinical Development of Larotrectinib

  • Munveer S. Bhangoo
  • Darren SigalEmail author
Evolving Therapies (RM Bukowski, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Evolving Therapies


Purpose of Review

In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.

Recent Findings

The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. NTRK chromosomal alterations, most commonly gene fusions, have been identified as driver mutations in a broad range of malignancies. Small molecule tyrosine kinase inhibitors of Trk, including larotrectinib, have shown broad clinical activity across multiple tumor types with NTRK fusion events.


Although the prevalence of NTRK alterations is low, the exceptional activity of larotrectinib makes NTRK alterations an important predictive biomarker to screen for in any cancer.


NTRK TRK inhibitor Larotrectinib Precision medicine Personalized medicine Targeted oncology 


Compliance with Ethical Standards

Conflict of Interest

Munveer S. Bhangoo declares that he has no conflict of interest.

Darren Sigal has a patent issued on a method of treating neuroendocrine tumors.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell Mol Life Sci. 2006;63(13):1523–37.CrossRefGoogle Scholar
  2. 2.
    Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett. 2001;169(2):107–14.CrossRefGoogle Scholar
  3. 3.
    Klein R, Jing SQ, Nanduri V, O’Rourke E, Barbacid M. The trk proto-oncogene encodes a receptor for nerve growth factor. Cell. 1991;65(1):189–97.CrossRefGoogle Scholar
  4. 4.
    Kheder ES, Hong DS. Emerging targeted therapy for tumors with NTRK fusion proteins. Clin Cancer Res. 2018;24(23):5807–14.Google Scholar
  5. 5.
    Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature. 1991;350(6314):158–60.CrossRefGoogle Scholar
  6. 6.
    Kawamura K, Kawamura N, Fukuda J, Kumagai J, Hsueh AJW, Tanaka T. Regulation of preimplantation embryo development by brain-derived neurotrophic factor. Dev Biol. 2007;311(1):147–58.CrossRefGoogle Scholar
  7. 7.
    Kawamura K, Kawamura N, Sato W, Fukuda J, Kumagai J, Tanaka T. Brain-derived neurotrophic factor promotes implantation and subsequent placental development by stimulating trophoblast cell growth and survival. Endocrinology. 2009;150(8):3774–82.CrossRefGoogle Scholar
  8. 8.
    Kawamura K, Kawamura N, Kumazawa Y, Kumagai J, Fujimoto T, Tanaka T. Brain-derived neurotrophic factor/tyrosine kinase B signaling regulates human trophoblast growth in an in vivo animal model of ectopic pregnancy. Endocrinology. 2011;152(3):1090–100.CrossRefGoogle Scholar
  9. 9.
    Loeb DM, Stephens RM, Copeland T, Kaplan DR, Greene LA. A Trk nerve growth factor (NGF) receptor point mutation affecting interaction with phospholipase C-gamma 1 abolishes NGF-promoted peripherin induction but not neurite outgrowth. J Biol Chem. 1994;269(12):8901–10.PubMedGoogle Scholar
  10. 10.
    Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.CrossRefGoogle Scholar
  11. 11.
    Miranda C, Mazzoni M, Sensi M, Pierotti MA, Greco A. Functional characterization of NTRK1 mutations identified in melanoma. Genes Chromosom Cancer. 2014;53(10):875–80.CrossRefGoogle Scholar
  12. 12.
    Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A, et al. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell. 2004;6(4):347–60.CrossRefGoogle Scholar
  13. 13.
    Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25–34.CrossRefGoogle Scholar
  14. 14.
    Greco A, Miranda C, Pierotti MA. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):44–9.CrossRefGoogle Scholar
  15. 15.
    Rubin JB, Segal RA. Growth, survival and migration: the Trk to cancer. Cancer Treat Res. 2003;115:1–18.PubMedGoogle Scholar
  16. 16.
    Sigal DS, Bhangoo MS, Hermel JA, Pavlick DC, Frampton G, Miller VA, et al. Comprehensive genomic profiling identified novel NTRK fusions in neuroendocrine tumors. Oncotarget. 2018;9(88):35809–12.Google Scholar
  17. 17.
    Hyman DM, Laetsch TW, Kummar S, DuBois SG, Farago AF, Pappo AS, et al. The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. J Clin Oncol. 2017;35(18_suppl):LBA2501.CrossRefGoogle Scholar
  18. 18.
    Chen Y, Chi P. Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 2018 7 [cited 2018 Aug 28];11. Available from:
  19. 19.
    • Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, et al. Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer. J Natl Compr Cancer Netw. 2017;15(11):1317–22 This paper highlights the utility of NTRK inhibition in a patient with metastatic neuroendocrine tumor, a tumor type not previously known to exhibit targetable driver mutations. CrossRefGoogle Scholar
  20. 20.
    Liu D, Offin M, Harnicar S, Li BT, Drilon A. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–52.CrossRefGoogle Scholar
  21. 21.
    • Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367–76 This report characterizes the molecular pathogenesis of a secretory breast carcinoma, a rare histologic subtype associated with a TRK fusion event. CrossRefGoogle Scholar
  22. 22.
    Watanabe N, Kobayashi H, Hirama T, Kikuta A, Koizumi S, Tsuru T, et al. Cryptic t(12;15)(p13;q26) producing the ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in congenital mesoblastic nephroma with trisomy 11: fluorescence in situ hybridization and IGF2 allelic expression analysis. Cancer Genet Cytogenet. 2002;136(1):10–6.CrossRefGoogle Scholar
  23. 23.
    Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–7.CrossRefGoogle Scholar
  24. 24.
    Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015 Oct;5(10):1049–57.CrossRefGoogle Scholar
  25. 25.
    Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–72.CrossRefGoogle Scholar
  26. 26.
    Hong DS, Brose MS, Doebele RC, Shaw AT, Dowlati A, Bauer TM, et al. Abstract PR13: clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Mol Cancer Ther. 2015;14(12 Supplement 2):PR13.CrossRefGoogle Scholar
  27. 27.
    Burris HA, Shaw AT, Bauer TM, Farago AF, Doebele RC, Smith S, et al. Abstract 4529: pharmacokinetics (PK) of LOXO-101 during the first-in-human phase I study in patients with advanced solid tumors: interim update. Cancer Res. 2015;75(15 Supplement):4529.CrossRefGoogle Scholar
  28. 28.
    Bhangoo MS, Boasberg P, Mehta P, Elvin JA, Ali SM, Wu W, et al. Tumor mutational burden guides therapy in a treatment refractory POLE-mutant uterine carcinosarcoma. Oncologist. 2018;23(5):518–23.CrossRefGoogle Scholar
  29. 29.
    Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, et al. Biallelic deletion of PALB2 occurs across multiple tumor types and suggests responsiveness to poly (ADP-ribose) polymerase inhibition. JCO Precis Oncol. 2017;1:1–7.Google Scholar
  30. 30.
    Shukla N, Roberts SS, Baki MO, Mushtaq Q, Goss PE, Park BH, et al. Successful targeted therapy of refractory pediatric ETV6-NTRK3 fusion-positive secretory breast carcinoma. JCO Precis Oncol. 2017.
  31. 31.
    Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A. Infantile fibrosarcoma with NTRK3-ETV6 fusion successfully treated with the tropomyosin-related kinase inhibitor LOXO-101. Pediatr Blood Cancer. 2016;63(8):1468–70.CrossRefGoogle Scholar
  32. 32.
    Hong DS, Dowlati A, Burris HA III, Lee JJ, Brose MS, Farago AF, et al. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Eur J Cancer. 2017;72:S148.CrossRefGoogle Scholar
  33. 33.
    Ziegler DS, Wong M, Mayoh C, Kumar A, Tsoli M, Mould E, et al. Brief report: potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma. Br J Cancer. 2018;119(6):693–6.CrossRefGoogle Scholar
  34. 34.
    DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018;124(21):4241–7.Google Scholar
  35. 35.
    •• Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9 Landmark study reporting the safety and efficacy results of three early-phase clinical trials utilizing larotrectinib across multiple tumor types (pediatric and adults). CrossRefGoogle Scholar
  36. 36.
    Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–72.CrossRefGoogle Scholar
  37. 37.
    Zhai D, Deng W, Huang J, Rogers E, Cui JJ. Abstract 3161: TPX-0005, an ALK/ROS1/TRK inhibitor, overcomes multiple resistance mechanisms by targeting SRC/FAK signaling. Cancer Res. 2017;77(13 Supplement):3161.CrossRefGoogle Scholar
  38. 38.
    Kozaki R, Yoshizawa T, Tsukamoto K, Kato H, Kawabata K. Abstract 2954A: a potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants. Cancer Res. 2016 Jul 15;76(14 Supplement):2954A.CrossRefGoogle Scholar
  39. 39.
    Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–47.Google Scholar
  40. 40.
    •• Benayed R, Offin MD, Mullaney KA, Sukhadia P, Rios KM, Desmeules P, et al. Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays. J Clin Oncol. 2018;36(15_suppl):12076 This study emphasizes the sensitivity of RNA sequencing techniques which may identify TRK fusions not seen with conventional DNA sequencing. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Scripps Clinic, Division of Hematology-OncologyLa JollaUSA

Personalised recommendations